Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 294-312 , February 2010

Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention

  • Harald E. Vonkeman, MD, PhD

      Affiliations

    • Rheumatologist, Epidemiologist, Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital Group and University of Twente, Enschede, The Netherlands
    • Corresponding Author InformationAddress reprint requests to H. E. Vonkeman, MD, PhD, Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital Group and University of Twente, PO Box 50.000, 7500 KA, Enschede, The Netherlands
    • ,
  • Mart A.F.J. van de Laar, MD, PhD

      Affiliations

    • Professor of Rheumatology, Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital Group and University of Twente, Enschede, The Netherlands

References 

  1. Hawkey CJ. COX-2 chronology. Gut. 2005;54:1509–1514
  2. http://www.botgard.ucla.edu/html/botanytextbooks/economicbotany/salix/Accessed June 2008
  3. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present and future. Am J Med. 2001;110:4S–7S
  4. Jack DB. One hundred years of aspirin. Lancet. 1997;350:437–439
  5. The Holy Bible, Romans 1:20
  6. Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond. 1763;53:195–200
  7. 100 years of Aspirin. Leverkussen: Bayer AG Consumer Care Business Group; 1997;
  8. History of paracetamol. http://www.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic5.htmlAccessed June 2008
  9. Dreser H. Pharmacologisches uber aspirin (acetylsalicyl-saure). Pflugers Arch. 1899;76:306
  10. History of aspirin. http://www.bayeraspirin.com/pain/asp_history.htmAccessed June 2008
  11. The Aspirin Foundation. http://www.aspirin-foundation.com/Accessed June 2008
  12. Douthwaite AH, Lintott SAM. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet. 1938;2:1222–1225
  13. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J. 1953;75:38–44
  14. O'Brian JR. Effects of salicylates on human platelets. Lancet. 1968;1:779–783
  15. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436–440
  16. von Euler US. Uber die spezifische blutdrucksenkende substanz des menschlichen prostate- und samenblasensekrets. Klin Wochenschr. 1935;14:1182–1183
  17. Goldblatt MW. Properties of human seminal plasma. J Physiol. 1935;84:208–218
  18. Kresge N, Simoni RD, Hill RL. The prostaglandins, Sune Bergström and Bengt Samuelsson. J Biol Chem. 2006;281:e9–e11
  19. Hamburg DA. Sune Bergstrom, biographical memoirs. Proc Am Philos Soc. 2007;151:92–96
  20. Van Dorp D, Beerthuis RK, Nugteren DH, Vonkeman H. Enzymatic conversion of ALL-CIS-polyunsaturated fatty acids into prostaglandins. Nature. 1964;203:839–841
  21. Van Dorp D, Beerthuis RK, Nugteren DH, Vonkeman H. The biosynthesis of prostaglandins. Biochim Biophys Acta. 1964;90:204–207
  22. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235
  23. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971;231:235–237
  24. Collier JG, Flower RJ. Effect of aspirin on human seminal prostaglandins. Lancet. 1971;2:852–853
  25. Adams SS. The discovery of brufen. Chem Br. 1987;23:1193–1195
  26. Jasani MK, Downie WW, Samuels BM, Buchanan WW. Ibuprofen in rheumatoid arthritis (Clinical study of analgesic and anti-inflammatory activity). Ann Rheum Dis. 1968;27:457–462
  27. Flower R, Gryglewski R, Herbaczynska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol. 1972;238:104–106
  28. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737–16740
  29. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994;367:243–249
  30. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. The structure of human cyclooxygenase2, conservation and flexibility of the NSAID binding size. Nat Struct Biol. 1996;3:927–933
  31. Hawkey CJ. Cox-2 inhibitors. Lancet. 1999;353:307–314
  32. Lanzo CA, Beechem JM, Talley J, Marnett LJ. Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy. Biochemistry. 1998;37:217–226
  33. Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med. 2001;110:12S–13S
  34. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075–1078
  35. Vonkeman HE, Fernandes RW, van de Laar MAFJ. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther. 2007;45:281–288
  36. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RN, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs (A randomized, double-blind, placebo-controlled trial). Ann Int Med. 1995;123:241–249
  37. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers (Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology). Am J Gastroenterol. 1998;93:2037
  38. Singh G, Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective—1997. J Rheumatol. 1998;25(Suppl 51):8–16
  39. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759
  40. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273
  41. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273–1275
  42. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pyloric campylobacter. Med J Aust. 1985;142:436–439
  43. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14
  44. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4:130
  45. Malfertheiner P, Labenz J. Does Helicobacter pylori status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology?. Am J Med. 1998;104:35–40S
  46. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–979
  47. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13
  48. Labenz J, Blum AL, Bolten WW, Dragosics B, Rösch W, Stolte M, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–335
  49. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet. 1998;352:1016–1021
  50. de Leest HT, Steen KS, Lems WF, Bijlsma JW, van de Laar MA, Huisman AM, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID-treatment: double-blind, randomized, placebo-controlled trial. Helicobacter. 2007;12:477–485
  51. Hirschowitz BI. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Gastroenterologist. 1994;2:207–223
  52. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut. 1987;28:527–532
  53. Vonkeman HE, Klok RM, Postma MJ, Brouwers JRBJ, van de Laar MAFJ. Direct medical costs of serious gastrointestinal ulcers among users of non steroidal anti-inflammatory drugs. Drugs Aging. 2007;24:681–690
  54. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344
  55. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296
  56. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159:649–657
  57. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169
  58. Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis. 2000;32(3):201–208
  59. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329:948
  60. Goldstein JL, Miner PB, Schlesinger PK, Liu S, Silberg DG. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2006;23:1189–1196
  61. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Simon L, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006;101:1747–1755
  62. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury (A meta-analysis of randomized controlled clinical trials). Arch Intern Med. 1996;156:2321
  63. Taha AS, Hudson NH, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435
  64. Bianchi Porro G, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol. 1997;92:663–667
  65. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223–227
  66. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. ASTRONAUT study group A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. New Engl J Med. 1998;338:719–726
  67. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442
  68. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106
  69. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip (Rofecoxib Phase III Protocol 035 Study Group). Arthritis Rheum. 2000;43:978
  70. Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford). 2002;41:1008
  71. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:470
  72. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis (The CLASS study: a randomized controlled trial). JAMA. 2000;284:1247–1255
  73. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davies B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis (VIGOR Study Group). N Engl J Med. 2000;343:1520–1528
  74. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369:465–473
  75. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665
  76. Cryer B, Feldman M. Effect of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17
  77. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719
  78. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs (Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group). N Engl J Med. 1998;338:727
  79. Bianchi Porro G, Lazzaroni M, Manzionna G, Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther. 1998;12:355
  80. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701–710
  81. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–2110
  82. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004;127:1038–1043
  83. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271–1278
  84. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low dose aspirin or naproxen. N Engl J Med. 2001;344:967–973
  85. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–1626
  86. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624–638
  87. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2001;346:2033
  88. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352:238
  89. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378
  90. Chan A. NSAIDs including aspirin: Role in prevention of colorectal cancer. UpToDate www.uptodate.comAccessed June 2008
  91. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S (Preventive Services Task Force). Ann Intern Med. 2007;146:365–375
  92. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S (Preventive Services Task Force). Ann Intern Med. 2007;146:376–389
  93. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol. 2002;89(Suppl):D26–D32
  94. Vonkeman HE, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular events. BMJ. 2006;332:895–898
  95. Topper JN, Cai J, Falb D, Gimbrone MA. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA. 1996;93:10417–10422
  96. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med. 2005;352:1092–1102
  97. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005;352:1071–1080
  98. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091
  99. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675
  100. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771
  101. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633–1644
  102. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? (Meta-analysis of randomised trials). BMJ. 2006;332:1302–1308
  103. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007 Mar 7;[Epub ahead of print]
  104. FDA Public Health Advisory: Alert for Healthcare Professionals Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). http://www.fda.gov/cder/drug/InfoSheets/HCP/NS_NSAIDsHCP.htmAccessed June 2008
  105. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001;345:1809
  106. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295
  107. Solomon DH. NSAIDs: cardiovascular effects. UpToDate www.uptodate.comaccessed June 2008
  108. Patrono C, Garcia Rodriguez LA, Landolfi R, Balgent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373
  109. Fitzgerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542
  110. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002;162:265–270
  111. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777
  112. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–1756
  113. Kaplan NM. NSAIDs and acetaminophen: effects on hypertension. UpToDate www.uptodate.comAccessed June 2008
  114. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490–496
  115. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204
  116. Rose BD, Post TW. NSAIDs: Acute renal failure and nephrotic syndrome. UpTo Date www.uptodate.comAccessed June 2008
  117. Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders. In: 5th ed.. New York (NY): McGraw-Hill; 2001;p. 192–196
  118. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164:881–889
  119. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet (A randomized, controlled trial). Ann Intern Med. 2000;133:1–9
  120. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563
  121. Stix G. Better ways to target pain. Sci Am. 2007;296:84–8688
  122. Scholich K, Geisslinger G. Is mPGES-1 a promising target for pain therapy?. Trends Pharm Sci. 2006;27:399–401
  123. Richardson CG, Chalmers A, Llewellyn-Thomas HA, Klinkhoff A, Carswell A, Kopec JA. Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol. 2007;34:1569–1575
  124. Chan FK. Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol. 2006;3:563–573

 There are no conflicts of interest and no sources of support.

PII: S0049-0172(08)00133-9

doi: 10.1016/j.semarthrit.2008.08.001

Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 294-312 , February 2010

Article Tools

* Image Usage & Resolution